A Japanese language version of Akili Interactive's EndeavorRx ground-breaking digital therapy for attention deficit hyperactivity disorder (ADHD) has started a phase 3 trial, with results d
Daiichi Sankyo has stepped up its efforts to bring a Japanese COVID-19 vaccine to patients, starting a new clinical trial of its mRNA-based candidate DS-5670 that focuses on its use as a bo
The Japanese regulator looks like it could follow the European Commission and reject approval of Biogen and Eisai's Alzheimer's disease therapy Aduhelm, leaving the FDA an outlier in its st
Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer.
The company’s senior vice president for major markets (Europe, Canada and Japan) talks about the continued evolution of pharma’s approach to communications and commercialisation.
Takeda has chalked up another milestone for its Alofisel cell therapy for a complication of Crohn's disease, becoming the first allogeneic stem cell therapy to be approved in Japan.